Sciele Pharma, Inc., a Shionogi company, announced the US availability of Adrenaclick, a single-dose, epinephrine auto-injector for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis. Adrenaclick will be available as a single unit or a convenient Two-Pack. It is also available in two dosing options (0.15 mg and 0.3 mg).

Adrenaclick delivers epinephrine, the drug of choice for anaphylactic reactions, with the use of an auto-injector. The Adrenaclick auto-injector is designed to ensure accurate delivery of epinephrine in the thigh through a “press-and-hold” administration technique. It is also designed for ease-of-use with clearly labeled caps, a red injector tip, and color-coded instructions on the side of the unit. Sciele is also offering free training information to help educate patients on the proper administration; full details are available online at www.adrenaclick.com.

Adrenaclick is indicated for the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as anaphylaxis to unknown substances or exercise-induced anaphylaxis.

Adrenaclick should only be injected into the anterolateral aspect of the thigh. Accidental injection into the hands or feet may result in loss of blood flow to the affected area and should be avoided.

Sciele Pharma, Inc., an indirect wholly owned subsidiary of Shionogi & Co., Ltd, is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on the therapeutic areas of cardiovascular, diabetes, women’s health and paediatrics.